MCRB MCRB
Company Profile ↓Company Overview
MCRB (MCRB) is a publicly traded company listed on with a market capitalization of $47.78M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Trades at an undemanding P/E of 7.8.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Trailing 12 Months Year-on-year growth — earnings +4088.2%.
- 5-Year Trend Long-term compounding — revenue CAGR -41.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -41.88% |
| 1 Year: | - |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | 4,088.24% |
Stock Price Performance
| 1 Year: | -66.14% |
| 6 Months: | -67.50% |
| 3 Months: | -33.27% |
| 1 Month: | -38.51% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)39.01 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
CONS
- Revenue declined at -41.9% CAGR over 5 years.
- Trading 82.5% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | 3.01M | - | - | 3.77M | 4.27M | 8.68M | - | 6.62M | 10.45M | 4.84M | - | 5.46M | 5.19M | 80.00K | 4.65M | 5.26M | 126.72M | 1.49M | 1.22M | 3.44M | - | - | - | - | - | - | - | 0 | 0 | 0 | 789.00K | 358.00K |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.53M | 1.69M | 736.00K | 592.00K | 0 |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -3.53M | -1.69M | -736.00K | 197.00K | 358.00K |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 23.71M | 23.19M | 21.74M | 19.57M | 21.27M |
| Operating Income | -12.34M | -14.56M | -19.79M | -19.92M | -28.14M | -19.09M | -25.69M | -25.89M | -28.42M | -7.31M | -29.77M | -28.27M | -28.14M | -22.21M | -21.67M | -24.55M | -10.95M | -17.18M | -19.19M | -19.69M | -20.55M | -30.00M | -35.33M | -48.14M | 68.41M | -55.75M | -63.33M | -59.11M | -70.57M | 49.52M | -44.59M | -34.44M | -28.87M | -29.17M | - | -27.24M | -24.88M | -22.48M | -19.38M | -20.91M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -26.16M | -18.80M | -21.43M | 81.24M | -20.13M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 32.68M | -19.86M | 8.20M | -15.34M | -19.91M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -12.55M | -14.62M | -19.63M | -19.70M | -27.91M | -18.69M | -25.27M | -25.47M | -28.02M | -6.93M | -28.95M | -27.92M | -27.79M | -21.95M | -21.29M | -24.33M | -10.76M | -16.41M | -18.78M | -19.88M | -20.71M | -30.28M | -35.47M | -48.33M | 68.22M | -56.62M | -64.73M | -60.00M | -71.17M | 46.55M | -47.85M | -40.13M | -32.87M | 88.78M | - | 32.68M | -19.86M | 8.20M | -15.34M | -19.91M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.36 | - | -0.53 | 0.72 | -0.61 | -0.70 | -0.49 | -0.57 | 0.36 | -0.37 | -5.49 | -4.34 | 11.63 | - | 3.75 | -2.27 | 0.94 | - | -2.08 |
| R&D Expense | 8.78M | 9.85M | - | 15.42M | 22.17M | 24.14M | - | 20.14M | 23.06M | 22.21M | - | 23.46M | 24.05M | 23.68M | - | 22.89M | 17.91M | 18.32M | - | 21.74M | 20.10M | 23.86M | 29.30M | 35.95M | 39.88M | 39.65M | 43.94M | 43.12M | 43.97M | 46.79M | 25.15M | 19.49M | 15.81M | 16.46M | - | 11.82M | 12.94M | 12.62M | - | 13.20M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 0 | 21.77M | 32.10M | 26.92M | 27.19M | 11.90M | 143.86M | 7.13M | 0 | 0 | 789.00K |
| Operating Income | -6.05M | -15.08M | -54.86M | -92.84M | -91.39M | -100.28M | -71.88M | -88.13M | -64.49M | -179.91M | -195.10M | -121.31M | -93.97M |
| Net Income | -6.10M | -16.71M | -54.78M | -91.58M | -89.38M | -98.94M | -70.28M | -89.13M | -65.58M | -250.16M | -113.72M | 136.00K | 5.70M |
| Diluted EPS | - | - | - | - | - | - | - | -1.12 | -0.72 | -2.31 | -17.77 | 0.00 | 0.64 |
| R&D Expense | 4.80M | 10.72M | 38.09M | 81.99M | 89.45M | 95.95M | 80.14M | 90.57M | 141.89M | 109.65M | 117.60M | 64.60M | 49.06M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 117.34M | 216.90M | 272.65M | 189.52M | 120.47M | 132.44M | 342.94M | - | 348.78M | 358.60M | 139.81M | 138.19M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | 194.76M | 175.41M | 38.67M | 49.38M |
| Cash & Equivalents | 6.21M | 1.65M | 114.19M | 73.93M | 54.54M | 36.09M | 85.82M | 65.13M | 116.05M | - | 163.03M | 127.97M | 30.79M | 45.77M |
| Inventory | - | - | - | - | - | - | - | - | - | - | 0 | 29.65M | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | 0 | - | 0 | 2.07M | 517.00K |
| Total Liabilities | - | - | 7.99M | 11.51M | 140.01M | 128.82M | 168.52M | 180.76M | 168.19M | - | 338.00M | 403.46M | 126.03M | 93.97M |
| Current Liabilities | - | - | 5.10M | 10.92M | 30.46M | 31.62M | 42.04M | 45.99M | 46.41M | - | 85.60M | 98.66M | 41.22M | 19.32M |
| Long Term Debt | - | - | - | - | - | - | - | 25.00M | 25.00M | 24.64M | 50.59M | 101.54M | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | 162.59M | 198.78M | 91.64M | 82.97M |
| Total Equity | -4.35M | -11.12M | -26.72M | 205.39M | 132.63M | 60.70M | -48.05M | -48.32M | 174.75M | - | 10.78M | -44.86M | 13.78M | 44.22M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | 6.26M | 6.75M | 8.65M | 9.56M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | 43.92M | -75.52M | -62.85M | -76.52M | -93.61M | 6.69M | -228.82M | -117.35M | -148.61M | 1.12M |
| Investing Cash Flow | - | - | - | -65.59M | 55.70M | 112.32M | -30.52M | -158.89M | 64.09M | 82.43M | 10.58M | 142.29M | -42.00K |
| Financing Cash Flow | - | - | - | 2.14M | 83.00K | 268.00K | 86.23M | 303.42M | 1.18M | 129.60M | 71.70M | -90.37M | 13.90M |
| Capital Expenditure | -174.00K | -1.00M | -4.36M | -21.49M | -4.68M | -1.94M | -1.00M | -591.00K | -9.57M | -9.82M | -7.97M | -380.00K | -252.00K |
| Free Cash Flow | - | - | - | 22.43M | -80.20M | -64.79M | -77.52M | -94.20M | -2.88M | -238.64M | -125.33M | -148.99M | 865.00K |
| Share Buybacks | - | - | - | - | 33.00K | - | - | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | -426.5% | -284.7% | -372.6% | -264.4% | -740.8% | -44.8% | -2,524.0% | - | - | -11,910.1% |
| Net Margin % | - | - | - | -420.7% | -278.4% | -367.6% | -258.5% | -749.2% | -45.6% | -3,509.5% | - | - | 721.9% |
| ROE % | 54.9% | 62.5% | -26.7% | -69.0% | -147.3% | 205.9% | 145.4% | -51.0% | - | -2,319.9% | 253.5% | 1.0% | 12.9% |
| ROCE % | - | -13.4% | -26.6% | -38.3% | -57.9% | -127.9% | -83.1% | -29.7% | - | -68.4% | -75.1% | -123.1% | -79.1% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MCRB
Seres Reports 80% Response in Colitis Linked to Cancer Therapy - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxNX3o2V19sSkNOaDIycjBsbTYtSHFhYWQzcEwxY2pRTHplQ0NKVTFvaGpNVGhjS3Fwc1JDcUU2cnpPSWNkaHFzZWRDU1k3aGt0cU8wQWZEQ1oxaW1ETThoSWV0dHhFME9XUEhfaWt4S0FLRFVSWTBuYThIV3l6Z1N2bnJjc2tOellWd0s0cT…
Seres Therapeutics Q2 Net Income Reaches $4.6 Million - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxNal9wUFUtWUlGYWFfQ3VaQ1hoSWtmbXZBaXNKSk1vcDdoTEt2cGlVVWlEMHNjQnJIUVhQYTYwWmlFYTNhYjd2ZUNfdlZrUDBFRnZpSEpYZTlzQjZhQllrZUNOSElzTGJ0bWdYcVl0ejBETHp0RWJXLVFRS1B2OTF3TFBLcExpVjlSaFZYV0…
Seres Therapeutics (MCRB) Q2 Revenue Surpasses Expectations Amid Clinical Progress - GuruFocus
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxQUW5jTVUwcjFKRTdzbGVvcjVXTDQ3UnlkRmNFSkdfUVVHdm5mWkpDRXNZMEo1SHJGb3dXNEhsZlBVajR1RnpQV1VXemlBRm1TSjRGXzF0d0ZJN0NjQi1xRjVGRHVlMmpnVHNYMlNKR0VLSV81SjlkcjRqb0VEMHJHXzBUbXVwOGZSc1JyNT…
MCRB Stock Declines As Seres Therapeutics Pauses SER-155 Phase 2 Study And Shrinks Headcount By 30% - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxPY2IwM0VMdUVLXzN2YzVLYlJSOVA1UV9RbE5aLU1zYU4xMGZjNVpDZVB0VWdtVlg3eVE5Tk9ybXM3X0FMcEhVRWwtRXVtVE5xNC1iVGJvbHZ2Sm03bmpfSmR6Um02Q05xSi1LZjJDWU1lNkN6bVYxSjZ2Z3Z6SVVNNVh5MXBWc3pJMS00SV…
Seres stock falls after pausing Phase 2 study and cutting workforce by 30% - Investing.com
<a href="https://news.google.com/rss/articles/CBMi0AFBVV95cUxNZml2bHI1cDRkcFRsYlRXUFFSR0hBeUt4dDlTelAzLW42eTc3ZUdiZ0xoYktDUVVUMGI1R05IV0FqMkowTGxvcWtCR0tCZ2R2T1hnSFYwMWJGelFEUE1UUTVYWVNUa0tsLU1ZNURuNHQ3TWVnZGdpd1RUdnl3MVktd0pmaHFDNjNVaFRoUG…
Seres Therapeutics to Host Webcast on July 8, 2026, to - GlobeNewswire
<a href="https://news.google.com/rss/articles/CBMi3wJBVV95cUxPUDBUc0Z4R3VSXzZGbEp0VklkOVZjcUowM0l2UFNmazJjcHVQdHZVTVRtMkx3UUdBZ01pOFRBcmFiZHB2eFRPcmE1MXpVMDNXTWFYdW4wN1MtLWd3UUwxQjNQWUJMM1FLR3VnQlZrajdzWVVickU1eGYxX0dzS1VhVGV0NU1JNGZzakVHRT…
MCRB — Frequently Asked Questions
What is the current share price of MCRB?
As of 2026-08-05 17:25 PDT, MCRB trades at $5.00 on NASDAQ/NYSE. Its 52-week range is $4.65 to $28.63.
What is the market capitalisation of MCRB?
MCRB has a market capitalisation of $47.78M on NASDAQ/NYSE.
What is the P/E ratio of MCRB?
MCRB trades at a trailing price-to-earnings (P/E) ratio of 7.81. Its price-to-book (P/B) ratio is 1.08.
What is the return on equity (ROE) of MCRB?
MCRB has a return on equity (ROE) of 12.88%. Its return on capital employed (ROCE) is -79.05%.
Is MCRB a good stock to buy?
This page provides a data-driven analysis of MCRB, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.